Compare United Airlines Holdings Inc (UAL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United Airlines Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? United Airlines Holdings Inc trades at $107.77 (market cap $35.76B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.6× United Airlines Holdings Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United Airlines Holdings Inc for 46 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| UAL | VRTX | |
|---|---|---|
Market Cap | $35.76B | $128.16B |
Volume | 5,327,551 | 806,603 |
Sector | Industrials | Health |
52-Week High | $136.11 | $557.96 |
52-Week Low | $85.21 | $407.37 |
Typical Hold Time | 46 Days | 120 Days |
Enterprise Value | $52.79B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
United Airlines (UAL) trades at $107.44, down 3.97% on the day, reflecting recent bearish technical signals. The stock shows strong fundamentals with a low P/E of 10.32 and consistent earnings beats, while analyst consensus remains strongly bullish with a $158.10 price target. Recent news highlights aggressive customer acquisition efforts targeting Delta's premium flyers with status-match offers and Starlink-enabled WiFi, signaling competitive growth initiatives.
UAL presents a compelling value opportunity with undervalued metrics and robust profitability, though near-term headwinds include rising fuel costs and technical weakness. The stock's upside potential is supported by solid earnings momentum and strategic positioning, but investors must weigh operational risks against the attractive valuation gap.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
